Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ...

Medically reviewed by Jennifer Steinhoff, MD The groin is located where the upper part of the thighs meets the lowest parts ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...

Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 ...

Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

AI can outperform human doctors when it comes to identifying ovarian cancer from ultrasound images.A new study publishe ...

GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company, and 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO) specializing in radiopharmaceuticals, are ...

A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform ...

A new international study shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images.

The findings, published in the journal Nature Medicine, showed that the AI models outperformed both expert and non-expert ...